Novel Piperine Compound Ab05 (N-5-(3,4-Dimethoxyphenyl)-2e,4e Pentadienylpiperidine) Inhibits H1n1 Influenza Virus Propagation In Vitro

Pandemic H1N1 influenza virus respiratory illness has become an inevitable global health concern. With antigenic drift, it becomes necessary to have drugs over tailor-made HIN1 vaccine every year. In the current study, we derivatized pure Piperine into N-5-(3,4-dimethoxyphenyl)-2E,4E-pentadienylpiperidine (AB05) and was initially screened for anti-H1N1influenza virus activity in-vitro on MDCK cell line. Initial cytotoxic doses of AB05 for the MDCK cell line were > 25 mu M. The results showed a dose-dependent reduction of the viral plaque's in the adsorption assay with EC 50 of 0.33 mu M. The mechanism of AB05 was by inhibition of matured viral release as evaluated by the time of virus addition with incubation of 6-10 hours. With the promising H1N1 virucidal activity of AB05, we included various strains of human influenza virus to screen AB05 inhibition of Neuraminidase (NA). The result showed 70% NA inhibition in WSN (H1N1), 90% in H3N2 & Influenza B and 49% in Tamiflu resistant H1N1). Together these observations illustrate Piperine derivative AB05an promising lead molecule to be further escalated to animal models.